Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies

Inclusion Criteria:

Histologically documented lymphoid malignancies, regardless of their origin (B,T or NK). These include ALL, CLL, HL, NHL, MM and PCL.
Patients must have failed at least one standard regimen of chemotherapy for their illness. They may have had unlimited prior regimens.
Performance status of ≤ 2 as per ECOG scale.
ALT < 2.5 times the upper limit of normal
Anticipated life expectancy of at least 12 weeks
Patients will be allowed to have baseline cytopenias, but ANC should be >200/μl and a platelet count > 25,000/ μl (within 2 weeks of starting therapy).
Patients must have a serum creatinine level ≤ 2 mg/dL (within 2 weeks of starting therapy).
Male or female adults of at least 18 years of age.
Signed written informed consent and willingness to meet follow-up schedule and study procedure obligations
Left Ventricular Ejection Fraction (LVEF) > 40% by echocardiogram or MUGA scan performed within 60 days prior to registration
Women and men of childbearing potential must agree to employ adequate contraception to prevent pregnancy while on therapy.

Exclusion Criteria:

Chemotherapy or radiotherapy received within the previous 2 weeks.
Uncontrolled, active infection requiring IV antibiotics.
Psychiatric illness that could potentially interfere with the completion of treatment according to this protocol.
Pregnant or potential for pregnancy.
Breast-feeding.
Prior asparaginase therapy complicated by pancreatitis, allergic reaction, hemorrhagic event, or thrombosis
Previous treatment with pegylated asparaginase
Prior doxorubicin exposure, more than 400 mg/m2
Clinically significant CHF
No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease free for at least three years. Prior malignancy is acceptable provided there has been no evidence of disease within the three year interval.